The American Thoracic Society (ATS) International Conference, scheduled from May 17-22 in San Diego, will host the unveiling of twenty-five abstracts featuring both approved and investigational medicines from Sanofi. Among the highlights are presentations on Dupixent® (dupilumab), developed in collaboration with Regeneron, showcasing its potential as a breakthrough treatment for patients grappling with chronic obstructive pulmonary disease (COPD) and asthma.
Late-breaking data from the NOTUS and BOREAS phase 3 studies, two pivotal trials, will demonstrate Dupixent’s efficacy as a potential first-in-class biologic therapy for certain adult patients with uncontrolled COPD characterized by type 2 inflammation. The BOREAS study will also present new insights into the predictive role of biomarkers in exacerbation improvement and other treatment responses.
Of particular note is the debut of phase 2b results for rilzabrutinib in asthma, laying the groundwork for its progression into a phase 3 program.
Dr. Naimish Patel, Global Head of Development, Immunology and Inflammation at Sanofi, remarked, “Our extensive presence at the ATS conference underscores our dedication to pioneering research in inflammatory respiratory conditions such as COPD and asthma. The data from the NOTUS and BOREAS trials for Dupixent deepen our comprehension of type 2 inflammation in COPD and highlight Dupixent’s potential as a groundbreaking biologic for COPD treatment. Additionally, we are excited to present promising data for rilzabrutinib and lunsekimig, showcasing their potential in asthma treatment. Our collective findings reflect our unwavering commitment to enhancing the lives of patients affected by debilitating respiratory illnesses.”
Dupixent The presentations will include new insights from the pivotal phase 3 Dupixent COPD program (NOTUS and BOREAS studies), revealing significant reductions in COPD exacerbations and improvements in lung function. The VESTIGE phase 4 study will also feature, demonstrating Dupixent’s effects on lung function in adult patients with uncontrolled moderate-to-severe asthma.
Clinical Data in COPD NOTUS study: Detailed efficacy and safety results will be presented in a late-breaking oral session, emphasizing Dupixent’s significant reduction in exacerbations in patients with uncontrolled COPD and evidence of type 2 inflammation. BOREAS study: Six abstracts will be presented, including an analysis of treatment-by-biomarker interaction effects in COPD patients and data on lung function. Clinical Data in Uncontrolled Moderate-to-Severe Asthma VESTIGE clinical study: Data on Dupixent’s impact on airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma will be featured. LIBERTY and VOYAGE studies: Additional analyses will include the impact of Dupixent on asthma duration and its efficacy in children aged 6-11 with uncontrolled moderate-to-severe asthma.
The safety results of these studies are consistent with Dupixent’s known safety profile in approved respiratory conditions.
Respiratory Pipeline The presentations will also include data on investigational compounds rilzabrutinib, an oral BTK inhibitor, and lunsekimig, a novel IL-13/TSLP Nanobody VHH, in asthma.
Phase 2b study of rilzabrutinib: Impact of treatment on loss of asthma control events, symptoms, and quality of life will be discussed. Lunsekimig: The presentation will delve into its impact on various immune cell and epithelial cell populations.
